Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of antiplatelet thrombolysin in preparation of medicament for treating von willebrand factor (VWF) defective thrombosis disease

An anti-platelet, defective technology, applied in the field of medicine, can solve problems such as ambiguity

Active Publication Date: 2013-08-28
ZHAOKE PHARMA HEFEI
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For VWF-deficient type, it is not clear whether antiplatelet thrombolysin can also inhibit platelet aggregation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of antiplatelet thrombolysin in preparation of medicament for treating von willebrand factor (VWF) defective thrombosis disease
  • Application of antiplatelet thrombolysin in preparation of medicament for treating von willebrand factor (VWF) defective thrombosis disease
  • Application of antiplatelet thrombolysin in preparation of medicament for treating von willebrand factor (VWF) defective thrombosis disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Inhibitory Effect of Antiplatelet Thrombolysin on Thrombus Formation in VWF Deficient Mouse Cremaster Arterial Thrombosis Model

[0024] Eight-week-old male wild-type mice and male VWF-deficient mice were anesthetized, and cremaster muscle samples were prepared for intravital microscopy under a dissecting microscope. Prewarmed bicarbonate-buffered saline was used for superperfusion throughout the experiment. Through jugular vein cannulation, rat anti-CD41 antibody (BD.Bioscience, 0.1 μg / g) and Alexa Flour647 goat anti-mouse IgG (Molecular Probes, 0.5 μg / g) were injected successively to obtain platelet labels. 30 minutes before the blood vessel injury, anti-platelet thrombolysin (6 μg / mL) or an equal volume of control buffer (which will not affect platelet aggregation) were administered through the jugular vein to the established mouse cremaster muscle arterial thrombus model. Laser-induced arterial thrombosis of the cremaster muscle was then used in multiple i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicaments, in particular to application of antiplatelet thrombolysin in preparation of a medicament for treating a von willebrand factor (VWF) defective thrombosis disease. Because a VWF defective organism does not contain VWF, the treatment effect of the antiplatelet thrombolysin on the VWF defective thrombosis disease is not realized by inhibiting the interaction of GPIb protein and VWF. Experiments show that after being treated by the antiplatelet thrombolysin, platelets aggregated in a wild mouse (containing the VWF in vitro) cremaster artery thrombus model are more than that of a VWF defective mouse, i.e., the effect of the antiplatelet thrombolysin on the VWF defective mouse is stronger than that of the wild mouse.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of an anti-platelet thrombolysin in the preparation of medicines for treating VWF-deficient vascular thrombosis diseases. Background technique [0002] The antiplatelet thrombolysin (Antiplatelet thrombolysin, APT) of the present invention is a kind of proteolytic enzyme isolated from the venom of Agkistrodon akistrodon, and is made up of two peptide chains of α chain and β chain, and the amino acid sequence of α chain is as SEQ As shown in ID NO.1, the amino acid sequence of the β chain is shown in SEQ ID NO.2. [0003] The current research results show that antiplatelet thrombolysin has obvious effects of dissolving fibrinogen and inhibiting platelet aggregation. Among them, the inhibitory effect of antithrombolysin on platelet aggregation is mainly through inhibiting the interaction between GPIb and VWF. GPIb is one of the most important glycoproteins on the surface of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/48A61P7/02
Inventor 倪合宇热合满阿迪力雷曦戴向荣李小羿
Owner ZHAOKE PHARMA HEFEI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com